Roman Vion
A5012549005- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Estrogen and related hormone effects
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- Cancer, Stress, Anesthesia, and Immune Response
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Inflammatory Biomarkers in Disease Prognosis
- Glioma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Advanced Breast Cancer Therapies
- Endometrial and Cervical Cancer Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiopharmaceutical Chemistry and Applications
- Lymphoma Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Monoclonal and Polyclonal Antibodies Research
- Multiple and Secondary Primary Cancers
Centre Henri Becquerel
2021-2025
Centre Virchow-Villermé
2021-2024
Inserm
2021-2024
Normandie Université
2021-2024
Université de Rouen Normandie
2021-2024
Abstract Background: Based on ASCENT, TROPICS-02 and DESTINY-Breast04 trials, SG T-DXd recently became approved for HER2low MBC. Since the payloads of both belong to same cytotoxic class (topoisomerase-1 inhibitor), cross-resistance is a potential concern. However, no data available efficacy one antibody drug conjugate (ADC) after another best therapeutic sequence has not been evaluated yet. Methods: We conducted retrospective study in 19 French comprehensive cancer centres. All patients...
<title>Abstract</title> Purpose: Pembrolizumab plus neoadjuvant chemotherapy (P-CT) is the new standard in early-stage triple-negative breast cancers (TNBC). impact on ovarian reserve remained unknown<bold>. </bold>We evaluated of pembrolizumab ovarian<bold> </bold>reserve, through plasmatic Anti-M<bold>ü</bold>llerian (AMH) analysis, young TNBC patients. Methods: <bold> </bold>TNBC patients £43 years treated by P-CT whose plasma samples were available before and after treatment included...
Immune checkpoint inhibitors (ICIs) are the standard of care for non-resectable non-small-cell lung cancer and under investigation resectable disease. Some authors have reported difficulties during surgery following ICI treatment. This retrospective study investigated perioperative outcomes resection in patients with preoperative ICI. Patients major after receiving ICIs were included as cases compared to who received chemotherapy without Surgical, clinical, imaging data collected. A total 25...
Background Cervical cancers are mainly caused by an oncogenic HPV. For locally advanced stages, the standard treatment is radio-chemotherapy (RTCT) followed brachytherapy. Nevertheless, prognosis remains highly heterogeneous between patients. Objective We investigated prognostic value of HPV circulating tumor DNA (ctDNA) in cervical alongside that Squamous Cell Carcinoma Antigen (SCC-A). Methods This single-center retrospective study included patients treated curative intent for IB3 to IVA...
6036 Background: Salvage chemotherapy after progression on immune checkpoint inhibitors (ICIs) was associated with an objective response rate (ORR) of 30% in patients (pts) recurrent/metastatic squamous cell carcinoma the head and neck (R/M SCCHN). We aimed to investigate efficacy taxanes + cetuximab (TC) +/- platinum pts R/M SCCHN who failed ICIs palliative setting. Methods: A retrospective study conducted at 7 French university hospitals. Eligibility criteria were treated ICI for SCCHN,...
<p>Association of RCB with clinicopathologic features and treatment in all patients. <b>A–C,</b> Forest plots showing the association RCB, either as class or continuous score, standard variables (A), sTILs (continuous %; B), (categorical; C) evaluated by regression analyses Analyses were performed on subset patients diagnosed treated at UZ Leuven, Belgium.</p>
<p>sTIL scoring and its association with clinicopathological features in all patients. <b>A,</b> Distribution of sTIL (continuous) the entire cohort subtypes. <b>B,</b> (category) <b>C,</b> Forest plots showing (categorical) standard clinicopathologic variables evaluated by regression analyses patients.</p>
<p>sTIL scoring and its association with clinicopathological features in all patients. <b>A,</b> Distribution of sTIL (continuous) the entire cohort subtypes. <b>B,</b> (category) <b>C,</b> Forest plots showing (categorical) standard clinicopathologic variables evaluated by regression analyses patients.</p>
<div>Abstract<p>Inflammatory breast cancer (IBC) is a rare (1%–5%), aggressive form of cancer, accounting for approximately 10% mortality. In the localized setting, standard care neoadjuvant chemotherapy (NACT) ± anti-HER2 therapy, followed by surgery. Here we investigated associations between clinicopathologic variables, stromal tumor-infiltrating lymphocytes (sTIL), and pathologic complete response (pCR), prognostic value pCR. We included 494 patients with IBC treated NACT from...
<p>Supplementary Figure 1 shows examples of sTIL scoring in skin on H&E images.</p>
<p>Association of pCR with OS. <b>A,</b> Kaplan–Meier curves OS according to pCR. <b>B,</b> Forest plots showing the association and standard clinicopathologic treatment variables quantified by Cox regression.</p>
<p>Association of pCR with clinicopathologic features and treatment in all patients. <b>A–C,</b> Forest plots showing the association standard variables (A), sTILs (continuous %; B), (categorical; C) evaluated by regression analyses patients.</p>
<p>Association of pCR with clinicopathologic features and treatment in all patients. <b>A–C,</b> Forest plots showing the association standard variables (A), sTILs (continuous %; B), (categorical; C) evaluated by regression analyses patients.</p>
<p>Supplementary Figure 12 shows analyses of the association RCB with DRFS.</p>
<p>Supplementary Figure 2 shows an overview of data flow in the study.</p>
<p>Supplementary Figure 13 shows analyses of the association sTIL with DFS and OS.</p>
<p>Supplementary Figure 11 shows analyses of the association RCB with DRF and OS.</p>
<p>Association of pCR with OS. <b>A,</b> Kaplan–Meier curves OS according to pCR. <b>B,</b> Forest plots showing the association and standard clinicopathologic treatment variables quantified by Cox regression.</p>
<p>Supplementary Figure 12 shows analyses of the association RCB with DRFS.</p>
<p>Supplementary Figure 13 shows analyses of the association sTIL with DFS and OS.</p>
<p>Supplementary Figure 11 shows analyses of the association RCB with DRF and OS.</p>
<p>Supplementary Figure 3 shows concordance of sTIL scoring between tumor and skin biopsies.</p>
<p>Baseline clinical and pathologic characteristics of patients in the entire cohort each breast cancer subgroups</p>